Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

Modern Pathology

Volumn 22, Issue 9, 2009, Pages 1169-1175

  Yeh, I Tien ^a   Martin, Mathew A ^a   Robetorye, Ryan S ^a   Bolla, Aswani R ^a   McCaskill, Chris ^b   Shah, Rashmi K ^b   Gorre, Mercedes E ^b   Mohammed, Mansoor S ^b   Gunn, Shelly R ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Combimatrix Molecular Diagnostics ^*  (United States)

Author keywords

Array comparative genomic hybridization; HER2; Polysomy 17; Validation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CHROMOSOME 17; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYSOME; PRIORITY JOURNAL; VALIDATION STUDY;

BREAST NEOPLASMS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CHROMOSOMES, HUMAN, PAIR 17; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; REPRODUCIBILITY OF RESULTS;

EID: 69549124028     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.78     Document Type: Article

References (28)

1. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-428. (Pubitemid 28524507)
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
3. Barrett C, Magee H, O'Toole D, et al. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 2007;60:690-693.
4. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008;61:89-94. (Pubitemid 351158232)
5. Tuma RS. Inconsistency of HER2 test raises questions. J Natl Cancer Inst 2007;99:1064-1065.
6. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869-4874.
7. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-114. (Pubitemid 36197611)
8. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002;15:137-145. (Pubitemid 34171323)
9. Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 2001;7:337-344. (Pubitemid 33101639)
10. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579. (Pubitemid 44650922)
11. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R267-R273.
12. Press MF. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified? Am J Clin Pathol 2006;126:673-674.
13. Troxell ML, Bangs CD, Lawce HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006;126:709-716. (Pubitemid 44707621)
14. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407. (Pubitemid 27520090)
15. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-211. (Pubitemid 28455458)
16. Albertson DG. Profiling breast cancer by array CGH. Breast Cancer Res Treat 2003;78:289-298.
17. Naylor TL, Greshock J, Wang Y, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res 2005;7:R1186-R1198.
18. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res 2006;8:210.
19. Climent J, Garcia JL, Mao JH, et al. Characterization of breast cancer by array comparative genomic hybridization. Biochem Cell Biol 2007;85:497-508. (Pubitemid 47518044)
20. Bejjani BA, Shaffer LG. Application of array-based comparative genomic hybridization to clinical diagnostics. J Mol Diagn 2006;8:528-533. (Pubitemid 44774149)
21. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004;101:1039-1044. (Pubitemid 38160580)
22. Patel A, Kang SH, Lennon PA, et al. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol 2008;83:540-546. (Pubitemid 351874869)
23. Gunn SR, Mohammed MS, Gorre ME, et al. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 2008;10:442-451.
24. Arriola E, Marchio C, Tan DS, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88:491-503. (Pubitemid 351581454)
25. Florell SR, Coffin CM, Holden JA, et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol 2001;14:116-128.
26. Robetorye RS, Gunn SR, Yeh I. A Tumor-Targeted DNA Extraction Method for Array CGH Analysis of HER2 Gene Copy Number Status in Newly Diagnosed Breast Cancer. United States and Canadian Academy of Pathology. Nature Publishing Group: Boston, MA, 2009.
27. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854. (Pubitemid 34705057)
28. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.